Acne Blog

Asthma is not in a position to help patients with acne drug - The asthma drug Zyflo in patients with severe acne, according to a mid-stage study, carried out by the company Critical Therapeutics Inc. The drug, known Also as zileuton, was not under better control the number of inflammatory lesions than placebo in business statistics.

Help the asthma drug Zyflo not in patients with severe acne, according to a study of middle phase, the company Critical Therapeutics Inc. The drug, also known as zileuton, was neither better control the number of inflammatory lesions than placebo in business statistics.

During the 12-week study, patients treated with Zyflo had an average reduction of 11.5 inflammatory lesions. Also statistical significance - that, compared with a reduction of 9.1 lesions in a group of patients who received placebo.

Patients treated with placebo showed a reduction of 16.4 lesions in the placebo group, but patients treated with Zyflo, showed an average reduction in the total number of lesions of 25.3.

The company said the drug showed a trend of potential benefit for some patients, although the drug is not the primary objective of the study.

Linda Lennox, a company spokesman, said the company could be a larger study, which collected the drug as a treatment for acne, with information from the small "proof of concept" study.

The company, which said in Lexington, Massachusetts, we continue to analyze the data and to cooperate with investigators. Further interpretation of results

Zyflo blocks inflammation causes enzyme called 5-lipoxygenase (5-LO). It approved "by the regulatory authorities of the United States in 1996 for the treatment of elderly patients with asthma and 12 years. Currently, the drug of Abbott Laboratories Inc., which is one of a number of years before selling licenses Critical Therapeutics at the end of 2003.